Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis

Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis

Bedaquiline (BDQ) is a known tuberculosis treatment, but the precise mechanism of cell death is unclear. Here, the authors explore the metabolic profiles of M. tuberculosis upon BDQ treatment and find reliance on glycolysis and synergistic cell death when oxidative phosphorylation is also targeted.

Guardado en:
Detalles Bibliográficos
Autores principales: Jared S. Mackenzie, Dirk A. Lamprecht, Rukaya Asmal, John H. Adamson, Khushboo Borah, Dany J. V. Beste, Bei Shi Lee, Kevin Pethe, Simon Rousseau, Inna Krieger, James C. Sacchettini, Joel N. Glasgow, Adrie J. C. Steyn
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/d680f868a7c742a69cdc3f6e9206d15b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Bedaquiline (BDQ) is a known tuberculosis treatment, but the precise mechanism of cell death is unclear. Here, the authors explore the metabolic profiles of M. tuberculosis upon BDQ treatment and find reliance on glycolysis and synergistic cell death when oxidative phosphorylation is also targeted.

Ejemplares similares